PRE-THERAPY FUNCTIONAL IMAGING AS A TOOL FOR PERSONALIZED TREATMENT SELECTION IN PHEOCHROMOCYTOMA AND PARAGANGLIOMA: A THERANOSTIC PERSPECTIVE
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6482Keywords:
Pheochromocytoma, Paraganglioma, Functional Imaging, Theranostics, Tumor Heterogeneity, Personalized MedicineAbstract
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors with heterogeneous biological behavior, requiring individualized diagnostic and therapeutic strategies. This review aimed to evaluate the role of functional imaging, particularly [^123I]I-MIBG scintigraphy and [^68Ga]Ga-DOTATATE PET/CT, in guiding personalized treatment selection within a theranostic framework. A comprehensive literature review was performed using PubMed and other scientific databases, including clinical studies, systematic reviews, retrospective analyses, and international guidelines. The analysis focused on diagnostic performance, molecular imaging characteristics, genotype–phenotype associations, tumor heterogeneity, and the impact of imaging findings on radionuclide therapy selection.
[^68Ga]Ga-DOTATATE PET/CT demonstrated superior sensitivity, especially in metastatic PPGLs and SDHB-associated disease, and enabled identification of patients potentially eligible for peptide receptor radionuclide therapy (PRRT). Although less sensitive, [^123I]I-MIBG scintigraphy remains essential for selecting candidates for [^131I]I-MIBG therapy. Functional imaging revealed substantial interlesional heterogeneity, reflecting differences in receptor expression and tumor biology that may influence treatment response.
Functional imaging is a fundamental component of precision management in PPGLs. The integration of molecular imaging with therapeutic radionuclide approaches enables identification of the predominant molecular target and supports individualized treatment decisions. MIBG scintigraphy and [^68Ga]Ga-DOTATATE PET/CT should be considered complementary modalities within a comprehensive theranostic strategy.
References
Carrasquillo, J. A., Chen, C. C., Jha, A., Ling, A., Lin, F. I., Pryma, D. A., & Pacak, K. (2021a). Imaging of pheochromocytoma and paraganglioma. Journal of Nuclear Medicine, 62(8), 1033–1042. https://doi.org/10.2967/jnumed.120.259689
Carrasquillo, J. A., Chen, C. C., Jha, A., Pacak, K., Pryma, D. A., & Lin, F. I. (2021b). Systemic radiopharmaceutical therapy of pheochromocytoma and paraganglioma. Journal of Nuclear Medicine, 62(9), 1192–1199. https://doi.org/10.2967/jnumed.120.259697
Chang, C. A., Pattison, D. A., Tothill, R. W., Kong, G., Akhurst, T. J., Hicks, R. J., & Hofman, M. S. (2016). 68Ga-DOTATATE and 18F-FDG PET/CT in paraganglioma and pheochromocytoma: Utility, patterns and heterogeneity. Cancer Imaging, 16(1), 22. https://doi.org/10.1186/s40644-016-0084-2
de Jong, M., Valkema, R., Jamar, F., Kvols, L. K., Kwekkeboom, D. J., Breeman, W. A. P., Bakker, W. H., Smith, C., Pauwels, S., & Krenning, E. P. (2002). Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Seminars in Nuclear Medicine, 32(2), 133–140. https://doi.org/10.1053/snuc.2002.31027
García-Vioque, V., Pedraza-Arévalo, S., Moreno-Montilla, M. T., Rivero-Cortés, E., Blázquez-Encinas, R., Mangili, F., Arroba, E., Herrera-Martínez, A. D., Culler, M. D., Gálvez-Moreno, M. Á., Barlier, A., Botella, L. M., Robledo, M., Castaño, J. P., & Ibáñez-Costa, A. (2026). Functional profiling of somatostatin receptors identifies somatostatin receptor subtype 2 as a vulnerability in succinate dehydrogenase SDHB-deficient pheochromocytomas and paragangliomas. Molecular Biomedicine, 7(1). https://doi.org/10.1186/s43556-026-00440-5
Hedeer, F., Oddstig, J., Hallgrimson, P., & Fagher, K. (2025). Multi-molecular imaging showing tumour heterogeneity and differing diagnostic performance in a case with metastatic pheochromocytoma. EJNMMI Reports, 9(1), 33. https://doi.org/10.1186/s41824-025-00267-3
Higuchi, T., Klimek, K., Groener, D., Chen, X., & Werner, R. A. (2025). Norepinephrine transporter-targeted cancer theranostics: New horizons. Clinical Nuclear Medicine, 50(1), 44–51. https://doi.org/10.1097/RLU.0000000000005567
Iravani, A., Parihar, A. S., Akhurst, T., & Hicks, R. J. (2022). Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms. Cancer Imaging, 22(1), 55. https://doi.org/10.1186/s40644-022-00465-3
Jaiswal, S. K., Sarathi, V., Memon, S. S., Garg, R., Malhotra, G., Verma, P., Shah, R., Sehemby, M. K., Patil, V. A., Jadhav, S., Lila, A. R., Shah, N. S., & Bandgar, T. R. (2020). 177Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma. Endocrine Connections, 9(9), 864–873. https://doi.org/10.1530/EC-20-0292
Janssen, I., Blanchet, E. M., Adams, K., Chen, C. C., Millo, C. M., Herscovitch, P., Taieb, D., Kebebew, E., Lehnert, H., Fojo, A. T., & Pacak, K. (2015). Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clinical Cancer Research, 21(17), 3888–3895. https://doi.org/10.1158/1078-0432.CCR-14-2751
Janssen, I., Chen, C. C., Millo, C. M., Ling, A., Taieb, D., Lin, F. I., Adams, K. T., Wolf, K. I., Herscovitch, P., Fojo, A. T., Buchmann, I., Kebebew, E., & Pacak, K. (2016a). PET/CT comparing 68Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 43(10), 1784–1791. https://doi.org/10.1007/s00259-016-3357-x
Janssen, I., Chen, C. C., Taieb, D., Patronas, N. J., Millo, C. M., Adams, K. T., Nambuba, J., Herscovitch, P., Sadowski, S. M., Fojo, A. T., Buchmann, I., Kebebew, E., & Pacak, K. (2016b). 68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI. Journal of Nuclear Medicine, 57(2), 186–191. https://doi.org/10.2967/jnumed.115.161018
Jha, A., Patel, M., Ling, A., Shah, R., Chen, C. C., Millo, C., Nazari, M. A., Sinaii, N., Charles, K., Kuo, M. J. M., Prodanov, T., Saboury, B., Talvacchio, S., Derkyi, A., del Rivero, J., O’Sullivan Coyne, G., Chen, A. P., Nilubol, N., Herscovitch, P., … Pacak, K. (2024). Diagnostic performance of [68Ga]DOTATATE PET/CT, [18F]FDG PET/CT, MRI of the spine, and whole-body diagnostic CT and MRI in the detection of spinal bone metastases associated with pheochromocytoma and paraganglioma. European Radiology, 34(10), 6488–6498. https://doi.org/10.1007/s00330-024-10652-4
Jha, A., Taieb, D., Carrasquillo, J. A., Pryma, D. A., Patel, M., Millo, C., de Herder, W. W., del Rivero, J., Crona, J., Shulkin, B. L., Virgolini, I., Chen, A. P., Mittal, B. R., Basu, S., Dillon, J. S., Hope, T. A., Aparici, C. M., Iagaru, A. H., Hicks, R. J., … Pacak, K. (2021). High-specific-activity-131I-MIBG versus 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma. Clinical Cancer Research, 27(11), 2989–2995. https://doi.org/10.1158/1078-0432.CCR-20-3703
Juhlin, C. C., & Mete, O. (2024). Hot trends in pheochromocytoma and paraganglioma: Are we getting closer to personalized dynamic prognostication? Turkish Journal of Pathology, 40(3), 143–148. https://doi.org/10.5146/tjpath.2024.13681
Leijon, H., Remes, S., Hagström, J., Louhimo, J., Mäenpää, H., Schalin-Jäntti, C., Miettinen, M., Haglund, C., & Arola, J. (2019). Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas. Human Pathology, 86, 66–75. https://doi.org/10.1016/j.humpath.2018.11.020
Maurice, J. B., Troke, R., Win, Z., Ramachandran, R., Al-Nahhas, A., Naji, M., Dhillo, W., Meeran, K., Goldstone, A. P., Martin, N. M., Todd, J. F., Palazzo, F., & Tan, T. (2012). A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 39(8), 1266–1270. https://doi.org/10.1007/s00259-012-2119-7
Mori, H., Wakabayashi, H., Saito, S., Nakajima, K., Yoshida, K., Hiromasa, T., & Kinuya, S. (2024). Evaluating the diagnostic efficacy of whole-body MRI versus 123I-mIBG/131I-mIBG imaging in metastatic pheochromocytoma and paraganglioma. Scientific Reports, 14(1), 13790. https://doi.org/10.1038/s41598-024-64607-2
Pacak, K., Blake, M. A., Sweeney, A. T., Jha, A., Imperiale, A., Zaidi, H., Raffaelli, M., Tüdös, Z., Timmers, H., Grossman, A., Nölting, S., & Taieb, D. (2026). Adrenal tumour imaging: Clinical, molecular, and radiomics perspectives. The Lancet Diabetes & Endocrinology, 14(1), 62–81. https://doi.org/10.1016/S2213-8587(25)00300-6
Patel, M., Tena, I., Jha, A., Taieb, D., & Pacak, K. (2021). Somatostatin receptors and analogs in pheochromocytoma and paraganglioma: Old players in a new precision medicine world. Frontiers in Endocrinology, 12, 625312. https://doi.org/10.3389/fendo.2021.625312
Prado-Wohlwend, S., del Olmo-García, M. I., Bello-Arques, P., & Merino-Torres, J. F. (2022). [177Lu]Lu-DOTA-TATE and [131I]MIBG phenotypic imaging-based therapy in metastatic/inoperable pheochromocytomas and paragangliomas: Comparative results in a single center. Frontiers in Endocrinology, 13, 778322. https://doi.org/10.3389/fendo.2022.778322
Scheuba, A., Kulterer, O. C., Lehner, R., Rybiczka-Tešulov, M., Esterbauer, H., & Raber, W. (2025). Metastatic pheochromocytoma/paraganglioma: Diagnostic performance of functional imaging (18F-fluoro-L-DOPA-, 68Ga-DOTA- and 18F-fluoro-deoxyglucose-based PET/CT) and of 123I-MIBG scintigraphy in 57 patients and 527 controls during long-term follow-up. Cancers, 17(23), 3855. https://doi.org/10.3390/cancers17233855
Shahrokhi, P., Emami-Ardekani, A., Harsini, S., Eftekhari, M., Fard-Esfahani, A., Fallahi, B., Ziarati, N. K., Akhlaghi, M., Farzanefar, S., Taheri, A. P. H., & Beiki, D. (2020). 68Ga-DOTATATE PET/CT compared with 131I-MIBG SPECT/CT in the evaluation of neural crest tumors. Asia Ocean Journal of Nuclear Medicine and Biology, 8(1), 8–17. https://doi.org/10.22038/aojnmb.2019.41343.1280
Taieb, D., Hicks, R. J., Hindie, E., Guillet, B. A., Avram, A., Ghedini, P., Timmers, H. J., Scott, A. T., Elojeimy, S., Rubello, D., Virgolini, I. J., Fanti, S., Balogova, S., Pandit-Taskar, N., & Pacak, K. (2019a). European Association of Nuclear Medicine practice guideline/Society of Nuclear Medicine and Molecular Imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 46(10), 2112–2137. https://doi.org/10.1007/s00259-019-04398-1
Taieb, D., & Pacak, K. (2018). Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. Cell and Tissue Research, 372(2), 393–401. https://doi.org/10.1007/s00441-018-2791-4
Taieb, D., Jha, A., Treglia, G., & Pacak, K. (2019b). Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocrine-Related Cancer, 26(11). https://doi.org/10.1530/ERC-19-0165
Tang, C. Y. L., Chua, W. M., Huang, H. L., Lam, W. W. C., Loh, L. M., Tai, D., Ong, S. Y. K., Yan, S. X., Loke, K. S. H., Ng, D. C. E., & Tham, W. Y. (2023). Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature. Journal of Neuroendocrinology, 35(12), e13349. https://doi.org/10.1111/jne.13349
te Beek, E. T., Burggraaf, J., Teunissen, J. J. M., & Vriens, D. (2023). Clinical pharmacology of radiotheranostics in oncology. Clinical Pharmacology & Therapeutics, 113(2), 260–274. https://doi.org/10.1002/cpt.2598
Timmers, H. J. L. M., Taieb, D., Pacak, K., & Lenders, J. W. M. (2024). Imaging of pheochromocytomas and paragangliomas. Endocrine Reviews, 45(3), 414–434. https://doi.org/10.1210/endrev/bnae001
Vyakaranam, A. R., Crona, J., Norlén, O., Granberg, D., Garske-Román, U., Sandström, M., Fröss-Baron, K., Thiis-Evensen, E., Hellman, P., & Sundin, A. (2019). Favorable outcome in patients with pheochromocytoma and paraganglioma treated with 177Lu-DOTATATE. Cancers, 11(7), 909. https://doi.org/10.3390/cancers11070909
Zhang, X., Wakabayashi, H., Hiromasa, T., Kayano, D., & Kinuya, S. (2023). Recent advances in radiopharmaceutical theranostics of pheochromocytoma and paraganglioma. Seminars in Nuclear Medicine, 53(4), 503–516. https://doi.org/10.1053/j.semnuclmed.2022.12.005
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Lesia Slobozheniuk, Yaryna Manila, Magdalena Bieniak, Aleksandra Skrobisz, Iga Maria Owczarek-Danowska, Dominik Zając, Julia Płóciennik, Julia Ołdak, Oleksandra Korshak, Olena Abramchuk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
